Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Abdomen Malignant Myxoid Leiomyosarcoma with PDGFRA and TP53 Missense Mutation: A Case Report

Author(s): Yao-xuan Li, Jian-ping Yu, Yan-qing Gong, Hai-fu Huang* and Xian-lin Wu*

Volume 20, Issue 5, 2024

Published on: 30 January, 2024

Page: [517 - 521] Pages: 5

DOI: 10.2174/0115733947276376231102103138

Price: $65

Abstract

Background: Malignant myxoid leiomyosarcoma (MMLS) is most commonly found in the uterus but can also occur in other areas, such as the extremities, vulva, chest wall, and abdominal cavity. This cancer is more prevalent in women and has a poor prognosis with a high rate of recurrence and a significant percentage of metastasis.

Case Representation: Herein, we report the case of a 64-year-old female patient who presented with 3-month history of left lower abdominal mass. The patient underwent abdominal malignancy resection and was subsequently diagnosed with myxoid leiomyosarcoma. The patient experienced a recurrence and metastasis with significant ascites after the initial surgery and did not respond to treatment with oral Anrotinib in combination with Tislelizumab immunotherapy. Further genetic testing using next-generation sequencing (NGS) identified missense mutations in the PDGFRA and TP53 genes in the patient's plasma, but no mutations in the KIT gene were detected. Immunohistochemical analysis of the tumor tissue also revealed a negative expression of PD-L1. As a result, we altered her targeted therapy to Avapritinib, which resulted in significant improvement in her symptoms, including abdominal distension and pain, a decrease in ascites, and the KPS score increased from 60 points before treatment to 90 points after treatment SD (stable disease) was achieved for three months after treatment.

Conclusion: In this case report, we present the instance of a patient with malignant myxoid leiomyosarcoma with a missense mutation in both the PDGFRA and TP53 genes. We found that targeted therapy with Avapritinib was effective in achieving a positive outcome in this patient. Our findings suggest that genetic detection is possible to better understand the biological behavior, genetic characteristics, and patient's response and tolerance to certain drugs, thus selecting the best treatment plan for the patient. Avapritinib may be a promising new treatment option for leiomyosarcoma patients with similar genetic mutations.

« Previous
Graphical Abstract

[1]
Trabelsi, A.; Mutijima, E.; El Hossini Soua, A. Primary myxoid leiomyosarcoma of the ovary. A case report with review of the literature. Tunis. Med., 2005, 83(5), 288-291.
[PMID: 16044903]
[2]
Shinya, T; Shibamoto, K; Maeba, K Magnetic resonance imaging findings of a myxoid leiomyosarcoma of the uterus: A case report and literature review. Eur J Radiol Open, 2021, 8, 100328.
[http://dx.doi.org/10.1016/j.ejro.2021.100328]
[3]
Holzmann, C.; Saager, C.; Mechtersheimer, G.; Koczan, D.; Helmke, B.M.; Bullerdiek, J. Malignant transformation of uterine leiomyoma to myxoid leiomyosarcoma after morcellation associated with ALK rearrangement and loss of 14q. Oncotarget, 2018, 9(45), 27595-27604.
[http://dx.doi.org/10.18632/oncotarget.25137] [PMID: 29963223]
[4]
Indio, V.; Astolfi, A.; Tarantino, G. Integrated molecular characterization of gastrointestinal stromal tumors (gist) harboring the rare d842v mutation in pdgfra gene. Int. J. Mol. Sci., 2018, 19(3), 732.
[http://dx.doi.org/10.3390/ijms19030732] [PMID: 29510530]
[5]
Indio, V.; Ravegnini, G.; Astolfi, A. Gene expression profiling of pdgfra mutant gist reveals immune signatures as a specific fingerprint of d842v exon 18 mutation. Front. Immunol., 2020, 11, 851.
[http://dx.doi.org/10.3389/fimmu.2020.00851]
[6]
Olivier, M.; Hollstein, M.; Hainaut, P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol., 2010, 2(1), a001008.
[http://dx.doi.org/10.1101/cshperspect.a001008] [PMID: 20182602]
[7]
Gai, Q.J.; Fu, Z.; He, J. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma. Signal Transduct. Target. Ther., 2022, 7(1), 33.
[http://dx.doi.org/10.1038/s41392-021-00855-2] [PMID: 35105853]
[8]
Hiwatari, M.; Taki, T.; Tsuchida, M. Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor α(PDGFRA) gene in childhood acute myeloid leukemia with t(8;21)(q22;q22) or inv(16)(p13q22). Leukemia, 2005, 19(3), 476-477.
[http://dx.doi.org/10.1038/sj.leu.2403638] [PMID: 15674355]
[9]
Grunewald, S.; Klug, L.R.; Mühlenberg, T. Resistance to avapritinib in pdgfra-driven gist is caused by secondary mutations in the pdgfra kinase domain. Cancer Discov., 2021, 11(1), 108-125.
[http://dx.doi.org/10.1158/2159-8290.CD-20-0487] [PMID: 32972961]
[10]
Schroeder, B.A.; Kohli, K.; O’Malley, R.B. Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab. OncoImmunology, 2020, 9(1), 1710064.
[http://dx.doi.org/10.1080/2162402X.2019.1710064] [PMID: 32002307]
[11]
Smrke, A.; Gennatas, S.; Huang, P.; Jones, R.L. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Future Oncol., 2020, 16(22), 1641-1648.
[http://dx.doi.org/10.2217/fon-2020-0348] [PMID: 32517495]
[12]
Jones, R.L.; Serrano, C.; von Mehren, M. Avapritinib in unresectable or metastatic pdgfra d842v-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the navigator phase I trial. Eur. J. Cancer, 2021, 145, 132-142.
[http://dx.doi.org/10.1016/j.ejca.2020.12.008]
[13]
Gotlib, J.; Reiter, A.; Radia, D.H. Efficacy and safety of avapritinib in advanced systemic mastocytosis: Interim analysis of the phase 2 pathfinder trial. Nat. Med., 2021, 27(12), 2192-2199.
[http://dx.doi.org/10.1038/s41591-021-01539-8] [PMID: 34873345]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy